Trouble at the Nasdaq Mothership. Must be those pesky Ruskies again!
Apple, Google and other Nasdaq Stocks Swing Wildly in After-Hours Trading
The prices of shares in some of the world’s biggest companies seemed to alternately plummet or soar in after-hours trading on Nasdaq Inc.’s flagship exchange.
Please tell me amgn split 2:1 today....
IGXT (MC $50 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!
2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $50 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .GL
MarketCap $50 Million Cash ~$12 Million (including convertible debt) =cash untill 2021+ Price: 0.80
NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July NDA resubmission for Rizaport (migraine) in early Q3 Partnership for Tadalafil in 2H 2017
IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.
Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.
IntelGenx has multi-faceted BD approach for its oral films
With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
amgn has formed a right cup with handle = super bullish!
whooz yor daddy
So what's gonna happen to biotechs if this aca healthcare bill can't get past the Senate?
Heading for a new 52 week high. Get onboard now before you miss out.
155 to 175 in a month. you decide now to buy?!
If you can't have faith in what is held up to you for faith, you must find things to believe in yourself, for a life without faith in something is too narrow a space to live.http://dataunion.tistory.com/10758
Amgen NASDAQ : AMGN Correlation Histogram
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.9 In other words, the correlation coefficient of the other stock
Andrew Peters, from Deutsche Bank rated AMGN a HOLD with only has a price target of $172 whereas GILD is a buy with a price target of $79. This guy has a success rating of 45% which means we are better off tossing a coin which has a 50% success rate. Investors who choose to believe him would have a 55% chance of picking a lemon. You can check his profile at this link below: https://www.tipranks.com/analysts/andrew-peters
Monster MicroCaps SPECIAL ALERT to AMGN shareholders – NWBO $.19 and climbing, just announced $11 million financing with convertible debt payable in 3 years at $0.25, $.50 and $1.00. NWBO expected to release final Phase III Trial results any day from now until mid-July. If results are comparable to preliminary data, shares likely to explode to yield enormous percentage gains. Announcement could be huge because DCVax-L and DCVax Direct are also proven effective against 13 common cancers and has only mild fever as potential side effect. This breakthrough immunotherapy might replace the $100 Billion chemotherapy market. https://finance.yahoo.com/news/nwbio-closes-3-convertible-debt-154100683.html
NWBio Closes 3-Year Convertible Debt Exchange and Financing, and Completes Payoff of Last $5 Million of 2014 Bonds
This completes the Company's payoff of $11 million in principal amount of bonds, plus associated interest and forbearance fees, over the period from March through June of this year in accordance with an installment payment agreement with the bondhold
out of favor biotech, coming out of 2 yr abyss.. AMGN fair PE, solid Divy, 4q of solid earnings,..very reasonable risk/reward.
Participating in group rally. Blue chip stock. If you want leverage, look at LABU...a 3x daily